David Toung downgraded Bristol-Myers Squibb from Buy to Hold, citing significant risks arising from the Celgene merger.
Bristol-Myers Squibb's growth prospects following the planned acquisition of Celgene are a cause of concern, Toung said in a Friday downgrade note. (See his track record here.)
The primary concern is the loss of exclusivity and patent cliff issue for Celgene's Revlimid, the analyst said.
Revlimid is Celgene's best-selling multiple myeloma drug and showed 15-percent year-over-year growth to $2.58 billion in the first quarter of 2019. It fetched roughly 64 percent of the company's revenues.
Toung said he's not confident about Celgene's pipeline delivering sufficient revenue to offset the eventual decline in Revlimid revenues when it loses its exclusivity in 2026.
Additionally, Bristol-Myers Squibb's Opdivo could come under pressure from Merck & Co., Inc. (NYSE: MRK)'s Keytruda, as the latter establishes its supremacy in the first-line treatment of non-small cell lung cancer, the analyst said.
Competition could also come from other new immuno-oncology drugs, he said.
The combined company will be weighed down by a heavy debt pile of more than $45 billion, restricting the use of cash for R&D, M&A and in-licensing of new assets, according to Argus.
The Price Action
Bristol-Myers Squibb shares were down 1.1 percent at $46.34 at the time of publication Monday, while Celgene shares were down 0.61 percent at $94.84.
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Outlook Therapeutics Rallies 150% In 2 Days: What You Need To Know
Latest Ratings for BMY
View More Analyst Ratings for BMY
View the Latest Analyst Ratings
See more from Benzinga
- 5 ASCO Abstracts That Moved Stocks
- The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi
- Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.